The role of the nonspecific inflammatory markers in determining the anatomic extent of venous thromboembolism

Clinical and Applied Thrombosis/Hemostasis

Volumn 21, Issue 2, 2015, Pages 181-185

  Bakirci, Eftal Murat ^a   Topcu, Selim ^b   Kalkan, Kamuran ^b   Tanboga, Ibrahim Halil ^b   Borekci, Abdurrezzak ^c   Sevimli, Serdar ^b   Acikel, Mahmut ^b  

^a Bayburt State Hospital   (Turkey)

^b ATATURK UNIVERSITY   (Turkey)

^c Sifa Hastaneler Grubu Erzurum Sifa Hastanesi   (Turkey)

Author keywords

deep venous thrombosis; pulmonary embolism; thrombosis

Indexed keywords

C REACTIVE PROTEIN; BIOLOGICAL MARKER;

ADULT; ARTICLE; BLOOD SAMPLING; CARDIOVASCULAR RISK; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; FEMALE; HUMAN; LEUKOCYTE; LEUKOCYTE DIFFERENTIAL COUNT; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MEAN CORPUSCULAR HEMOGLOBIN; MEAN CORPUSCULAR VOLUME; MIDDLE AGED; NEUTROPHIL LYMPHOCYTE RATIO; ORAL CONTRACEPTIVE USE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; THROMBOCYTE COUNT; THROMBOCYTE VOLUME; VENOUS THROMBOEMBOLISM; BLOOD; CLINICAL TRIAL; LYMPHOCYTE; LYMPHOCYTE COUNT; METABOLISM; NEUTROPHIL; PATHOLOGY; VEIN THROMBOSIS;

ADULT; BIOMARKERS; C-REACTIVE PROTEIN; FEMALE; HUMANS; LYMPHOCYTE COUNT; LYMPHOCYTES; MALE; MIDDLE AGED; NEUTROPHILS; PULMONARY EMBOLISM; RETROSPECTIVE STUDIES; VENOUS THROMBOEMBOLISM; VENOUS THROMBOSIS;

EID: 84923004995     PISSN: 10760296     EISSN: 19382723     Source Type: Journal    
DOI: 10.1177/1076029613494469     Document Type: Article

References (33)

1. Ginsberg JS. Management of venous thromboembolism. N Engl J Med. 1996 ; 335 (24). 1816-1828
2. Baglin T, Douketis J, Tosetto A, et al. Does the clinical presentation and extent of venous thrombosis predict likelihood and type of recurrence? A patient-level meta-analysis. J Thromb Haemost. 2010 ; 8 (11). 2436-2442
3. Reganon E, Vila V, Martinez-Sales V, et al. Sialic acid is an inflammation marker associated with a history of deep vein thrombosis. Thromb Res. 2007 ; 119 (1). 73-78
4. Roumen-Klappe EM, den Heijer M, van Uum SH, van der Ven-Jongekrijg J, van der Graaf F, Wollersheim H.. Inflammatory response in the acute phase of deep vein thrombosis. J Vasc Surg. 2002 ; 35 (4). 701-706
5. Reiter M, Bucek RA, Koca N, Dirisamer A, Minar E. Deep vein thrombosis and systemic inflammatory response: a pilot trial. Wien Klin Wochenschr. 2003 ; 115 (3-4). 111-114
6. Matos MF, Lourenço DM, Orikaza CM, Bajerl JA, Noguti MA, Morelli VM. The role of IL-6, IL-8 and MCP-1 and their promoter polymorphisms IL-6 -174GC, IL-8 -251AT and MCP-1 -2518AG in the risk of venous thromboembolism: a case-control study. Thromb Res. 2011 ; 128 (3). 216-220
7. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med. 1999 ; 340 (6). 448-454
8. Hald EM, Brækkan SK, Mathiesen EB, Njolstad I, Wilsgaard T, Brox J, Hansen JB. High-sensitivity C-reactive protein is not a risk factor for venous thromboembolism: the Tromso study. Haematologica. 2011 ; 96 (8). 1189-1194
9. Myers DD, Hawley AE, Farris DM, et al. P-selectin and leukocyte microparticles are associated with venous thrombogenesis. J Vasc Surg. 2003 ; 38 (5). 1075-1089
10. Vormittag R, Vukovich T, Schönauer V, et al. Basal high-sensitivity-C-reactive protein levels in patients with spontaneous venous thromboembolism. Thromb Haemost. 2005 ; 93 (3). 488-493
11. Roumen-Klappe EM, Janssen MC, Van Rossum J, et al. Inflammation in deep vein thrombosis and the development of post-thrombotic syndrome: a prospective study. J Thromb Haemost. 2009 ; 7 (4). 582-587
12. Korte WC, Wuillemin WA, Caliezi C, Riesen WF. CRP measured by a high sensitivity assay correlates with clinical probability (Wells score) testing for deep venous thrombosis. Thromb Haemost. 2004 ; 91 (4). 841-842
13. Folsom AR, Lutsey PL, Astor BC, Cushman M. C-reactive protein and venous thromboembolism: a prospective investigation in the ARIC cohort. Thromb Haemost. 2009 ; 102 (4). 615-619
14. Papa A, Emdin M, Passino C, Michelassi C, Battaglia D, Cocci F. Predictive value of elevated neutrophil-lymphocyte ratio on cardiac mortality in patients with stable coronary artery disease. Clin Chim Acta. 2008 ; 395 (1-2). 27-31
15. Gul M, Uyarel H, Ergelen M, et al. Predictive value of neutrophil to lymphocyte ratio in clinical outcomes of non-ST elevation myocardial infarction and unstable angina pectoris: a 3-year follow-up [Published online November 8, 2012]. Clin Appl Thromb Hemost. 2012 ;:
16. Buyukkaya E, Karakas MF, Karakas E, et al. Correlation of neutrophil to lymphocyte ratio with the presence and severity of metabolic syndrome[Published online September 18 2012]. Clin Appl Thromb Hemost. 2012 ;:
17. Reitsma PH, Rosendaal FR. Activation of innate immunity in patients with venous thrombosis: the Leiden Thrombophilia Study. J Thromb Haemost. 2004 ; 2 (4). 619-622
18. Etiopathogenesis of venous thrombosis and pulmonary thromboembolism: pathophysiologic changes in the cardiovascular system [in Turkish]. Anadolu Kardiyol Derg. 2001 ; 1 (1). 48-52
19. Oner F, Kaya A, Dogan R, Numanoglu N. Genetic risk factors of venous thromboembolism[in Turkish]. Tuberk Toraks. 2003 ; 51 (1). 60-69
20. Okyay K, Cemri M, Cengel A. Acute pulmonary embolism[in Turkish]. Anadolu Kardiyol Derg. 2005 ; 5 (3). 221-226
21. Prandoni P, Bilora F, Marchiori A, et al. An association between athero-sclerosis and venous thrombosis. N Engl J Med. 2003 ; 348 (15). 1435-1441
22. Hess K, Grant PJ. Inflammation and thrombosis in diabetes. Thromb Haemost. 2011 ; 105 (1). 43-54
23. Kaya MG, Yarlioglues M, Gunebakmaz O, et al. Platelet activation and inflammatory response in patients with non-dipper hypertension. Atherosclerosis. 2010 ; 209 (1). 278-282
24. Pearson TA, Mensah GA, Alexander RW, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003 ; 107 (3). 499-511
25. Lippi G, Favaloro EJ, Montagnana M, Franchini M. C-reactive protein and venous thromboembolism: causal or casual associ-ation?. Clin Chem Lab Med. 2010 ; 48 (12). 1693-1701
26. Quist-Paulsen P, Naess IA, Cannegieter SC, et al. Arterial cardiovascular risk factors and venous thrombosis: results from a population-based, prospective study (the HUNT 2). Haematologica. 2010 ; 95 (1). 119-125
27. Tsai AW, Cushman M, Rosamond WD, et al. Coagulation factors, inflammation markers, and venous thromboembolism: the longitudinal investigation of throm-boembolism etiology (LITE). Am J Med. 2002 ; 113 (8). 636-642
28. Glynn RJ, Danielson E, Fonseca FA, et al. A randomized trial of rosuvastatin in the prevention of venous thromboembolism. N Engl J Med. 2009 ; 360 (18). 1851-1861
29. Undas A, Celinska-Löwenhoff M, Kaczor M, Musial J. New nonlipid effects of statins and their clinical relevance in cardiovascular disease. Thromb Haemost. 2004 ; 91 (6). 1065-1077
30. Pepys MB, Hirschfield GM. C-reactive protein: a critical update. J Clin Invest. 2003 ; 111 (12). 1805-1812
31. Zahorec R. Ratio of neutrophil to lymphocyte counts-rapid and simple parameter of systemic inflammation and stress in critically ill. Bratisl Lek Listy. 2001 ; 102 (1). 5-14
32. Tamhane UU, Aneja S, Montgomery D, Rogers EK, Eagle KA, Gurm HS. Association between admission neutrophil to lympho-cyte ratio and outcomes in patients with acute coronary syndrome. Am J Cardiol. 2008 ; 102 (6). 653-657
33. Kaya H, Ertas F, Islamoglu Y, et al. Association between neutrophil to lymphocyte ratio and severity of coronary artery disease [Published online July 11, 2012]. Clin Appl Thromb Hemost. 2012 ;: